Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Hematology

Living Well with Chronic ITP: Monitoring and Quality of Life

At a Glance

Long-term management of chronic ITP focuses on balancing safety with your overall quality of life. While maintaining safe platelet counts is essential, modern care also prioritizes reducing fatigue, minimizing steroid use, and managing the risk of blood clots.

Living with chronic ITP is a marathon, not a sprint. While the initial diagnosis focuses on stabilizing your platelet count, long-term care—often called the survivorship phase—shifts toward balancing safety with your overall quality of life [1][2].

The Paradox of Risk: Bleeding vs. Clotting

It seems counterintuitive, but patients with ITP have a slightly higher risk of thrombosis (blood clots) than the general population, even though their platelet counts are low [3].

  • Venous and Arterial Risk: This includes risks for blood clots in the legs or lungs, as well as arterial events like stroke or heart attack [3][4].
  • The Balancing Act: Treatments like TPO-RAs (which stimulate platelet production) or surgeries like splenectomy can sometimes further increase this risk [5][6]. Your care team will monitor you for cardiovascular health and help you manage traditional risk factors like high blood pressure or smoking to keep your overall risk low [7].

Managing “Lab-Anxiety” and the Mental Toll

For many, the most difficult part of chronic ITP is the psychological burden of constant monitoring.

  • Lab-Anxiety: It is common to feel a surge of stress before a scheduled blood draw, often called “lab-anxiety.” The fear that a single low number might lead to a change in treatment or a hospital stay can be exhausting.
  • Remission Monitoring: If you are in long-term remission, your hematologist will likely increase the time between blood draws [8]. There is no “one size fits all” schedule, but the goal is to find the minimum frequency that keeps you safe while allowing you to “forget” about your ITP for weeks or months at a time.
  • Predicting Relapse: While specific markers like Mean Platelet Volume (MPV) are being studied as ways to predict if someone might relapse, most monitoring still relies on your symptoms and routine counts [9].

Quality of Life as a Treatment Goal

In the past, success in ITP was measured only by the platelet number. Today, experts recognize that Health-Related Quality of Life (HRQoL) is just as important [10][11].

  • Fatigue Management: Fatigue remains a major challenge for many living with chronic ITP [12]. It is essential to discuss this with your doctor, as moving away from long-term corticosteroids (steroids) toward newer treatments may help improve your energy levels and mood [13][14].
  • Steroid-Sparing Strategies: Because long-term steroid use is linked to weight gain, sleep disturbances, and bone thinning, the modern goal is to use the “least toxic” treatment that provides a durable response [13][8].

Looking Forward

It is entirely possible to live a full, active, and long life with ITP. For children, the outlook is especially bright, as many will eventually experience spontaneous remission and can safely taper off their medications [15][16]. For adults, chronic management is about shared decision-making—working closely with your hematologist to choose treatments that align with your personal goals, whether that means playing a sport, traveling, or simply having the energy to get through the day [2].

Return to the Home Page.

Common questions in this guide

Why do I have a risk of blood clots if my platelet count is low?
It seems counterintuitive, but ITP patients have a slightly higher risk of blood clots than the general population. Additionally, certain treatments like TPO-RAs or a splenectomy can further increase this risk.
How often do I need blood tests if my ITP is stable?
There is no one-size-fits-all schedule for lab work. If your counts are stable or you are in long-term remission, your hematologist will likely increase the time between blood draws to the minimum frequency needed to keep you safe.
Are there ways to treat ITP without using steroids long-term?
Yes, modern ITP care focuses on steroid-sparing strategies. Moving away from long-term corticosteroids to newer treatments can help reduce side effects like weight gain, bone thinning, sleep issues, and fatigue.
Is it normal to feel anxious before my ITP lab tests?
Yes, it is very common to experience 'lab-anxiety.' The fear that a single low platelet count could lead to a hospital stay or a change in your treatment plan is a recognized psychological challenge of living with chronic ITP.
Can children with ITP outgrow the condition?
Yes, the outlook for children with ITP is especially bright. Many children will eventually experience spontaneous remission and can safely taper off their medications over time under a doctor's supervision.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Now that my (or my child's) count is stable, what is the minimum frequency of blood draws I need for safe monitoring?
  2. 2.Given that I have ITP, how should we monitor my risk for blood clots (thrombosis) as I age or start new medications?
  3. 3.Are there steroid-sparing options we can consider to help improve my quality of life and reduce side effects?
  4. 4.How should we handle monitoring if I (or my child) am in long-term remission—at what point can we stop regular draws?
  5. 5.Can you help me understand which of my symptoms are related to ITP and which might be side effects of my current medications?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Proposal of treatment algorithm for immune thromocytopenia in adult patients of a hematology service at a referral center in Northeastern Brazil.

    Ribeiro RA, Galiza Neto GC, Furtado ADS, et al.

    Hematology, transfusion and cell therapy 2019; (41(3)):253-261 doi:10.1016/j.htct.2018.10.005.

    PMID: 31085155
  2. 2

    Second-line therapies in immune thrombocytopenia.

    Grace RF, Neunert C

    Hematology. American Society of Hematology. Education Program 2016; (2016(1)):698-706 doi:10.1182/asheducation-2016.1.698.

    PMID: 27913549
  3. 3

    Epidemiology and Clinical Manifestations of Immune Thrombocytopenia.

    Kohli R, Chaturvedi S

    Hamostaseologie 2019; (39(3)):238-249 doi:10.1055/s-0039-1683416.

    PMID: 30868551
  4. 4

    Is ITP a thrombophilic disorder?

    Rodeghiero F

    American journal of hematology 2016; (91(1)):39-45 doi:10.1002/ajh.24234.

    PMID: 26547507
  5. 5

    A Case of Eltrombopag-Induced Thrombotic Microangiopathy Initiating Hemodialysis.

    Fukuda H, Kitamura M, Sugiyama S, et al.

    Cureus 2024; (16(12)):e75947 doi:10.7759/cureus.75947.

    PMID: 39830571
  6. 6

    Eltrombopag Induced Thrombosis: A Case with Acute Myocardial Infarction.

    Gunes H, Kivrak T

    Current drug safety 2016; (11(2)):174-6 doi:10.2174/1574886311207040255.

    PMID: 26560493
  7. 7

    Cardiovascular and bleeding outcomes in a population-based cohort of patients with chronic immune thrombocytopenia.

    Adelborg K, Kristensen NR, Nørgaard M, et al.

    Journal of thrombosis and haemostasis : JTH 2019; (17(6)):912-924 doi:10.1111/jth.14446.

    PMID: 30933417
  8. 8

    Bleeding complications in immune thrombocytopenia.

    Arnold DM

    Hematology. American Society of Hematology. Education Program 2015; (2015()):237-42 doi:10.1182/asheducation-2015.1.237.

    PMID: 26637728
  9. 9

    Mean platelet volume at baseline and immune thrombocytopenia relapse in Chinese newly-diagnosed patients: a retrospective cohort study.

    Chen C, Song J, Wang Q, et al.

    Hematology (Amsterdam, Netherlands) 2018; (23(9)):646-652 doi:10.1080/10245332.2018.1461317.

    PMID: 29633664
  10. 10

    Health-Related Quality of Life and Burden of Fatigue in Chinese Patients with Immune Thrombocytopenia: A Cross-Sectional Study.

    Yang R, Yao H, Lin L, et al.

    Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2020; (36(1)):104-111 doi:10.1007/s12288-019-01124-7.

    PMID: 32158092
  11. 11

    Patterns and influences in health-related quality of life in children with immune thrombocytopenia: A study from the Dallas ITP Cohort.

    Flores A, Klaassen RJ, Buchanan GR, Neunert CE

    Pediatric blood & cancer 2017; (64(8)) doi:10.1002/pbc.26405.

    PMID: 28111877
  12. 12

    Risk Factors and Psychological Analysis of Chronic Immune Thrombocytopenia in Children.

    Sun Y, Long S, Liu W

    International journal of general medicine 2020; (13()):1675-1683 doi:10.2147/IJGM.S290459.

    PMID: 33408505
  13. 13

    Immune thrombocytopenia in two infant cases managed with eltrombopag.

    Ceglie G, Nocentini G, De Gennaro F, et al.

    Pediatric blood & cancer 2021; (68(9)):e29120 doi:10.1002/pbc.29120.

    PMID: 34047051
  14. 14

    Idiopathic Thrombocytopenic Purpura: Current Limitations and Management.

    Thakre R, Gharde P, Raghuwanshi M

    Cureus 2023; (15(11)):e49313 doi:10.7759/cureus.49313.

    PMID: 38143653
  15. 15

    Tapering and Sustained Remission of Thrombopoietin Receptor Agonists (TPO-RAs): Is it Time for Paediatric ITP?

    Marcos-Peña S, Fernández-Pernia B, Provan D, González-López TJ

    Advances in therapy 2024; (41(10)):3771-3777 doi:10.1007/s12325-024-02951-5.

    PMID: 39162982
  16. 16

    Intravenous immunoglobulin vs observation in childhood immune thrombocytopenia: a randomized controlled trial.

    Heitink-Pollé KMJ, Uiterwaal CSPM, Porcelijn L, et al.

    Blood 2018; (132(9)):883-891 doi:10.1182/blood-2018-02-830844.

    PMID: 29945954

This page explains long-term management and quality of life considerations for chronic ITP for educational purposes. Always consult your hematologist regarding your specific monitoring schedule and treatment plan.

Get notified when new evidence is published on Immune thrombocytopenia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.